hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06348212, orgStudyIdInfo id: 2022-11-008C, briefTitle: Effect of Probiotic Strain Lactobacillus Paracasei PS23 on Brain Fog in People With Long COVID, acronym: COVID-19, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-08, completionDateStruct date: 2025-12, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Taipei Veterans General Hospital, Taiwan, class: OTHER_GOV, descriptionModule briefSummary: The goal of this clinical trial is to test whether the intervention of probiotics supplement can improve symptoms of long covid syndrome.Participants will be given probiotics or placebo capsules for two month. Symptom questionnaires, cognitive function, eeg and fecal sample are recorded/collected before and after the supplement.Researchers will compare the probiotic group and the placebo to see if probiotic supplement really make differences., conditionsModule conditions: Long COVID, conditions: Brain Fog, conditions: Cognitive Change, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, maskingDescription: Randomization were performed by the provider of probiotic and placebo. The participant will never know their group. The study Investigator and Outcome assessor will not know the groups of participants until they finish recruiting and data processing., whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Lactobacillus paracasei PS23, interventions name: microcrystalline cellulose, outcomesModule primaryOutcomes measure: Long covid related symptoms, primaryOutcomes measure: Hospital Anxiety and Depression Scale, primaryOutcomes measure: The Pittsburgh sleep quality index, primaryOutcomes measure: Fatigue Severity Scale, primaryOutcomes measure: GI symptoms, primaryOutcomes measure: Cognitive function-Digit symbol substitution test, primaryOutcomes measure: Cognitive function-The Montreal Cognitive Assessment(MoCA), primaryOutcomes measure: Cognitive function-Color Trails making Test, primaryOutcomes measure: Cognitive function-Cogstate Brief Battery (CBB), primaryOutcomes measure: EEG, primaryOutcomes measure: Gut microbiota, primaryOutcomes measure: Fecal metabolite, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06348199, orgStudyIdInfo id: SB27-3004, briefTitle: A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-12, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2027-03, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-19, sponsorCollaboratorsModule leadSponsor name: Samsung Bioepis Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients. The main question it aims to answer is:• How effective the study drug is Participants will receive either investigational product (SB27 or Keytruda) and chemotherapy every 3 weeks.Researchers will compare SB27 and Keytruda to see if SB27 works in the same way as Keytruda., conditionsModule conditions: Non-small Cell Lung Cancer Stage IV, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 616, type: ESTIMATED, armsInterventionsModule interventions name: SB27, interventions name: Keytruda, outcomesModule primaryOutcomes measure: Objective response rate (ORR) at Week 24, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: SB Investigative Site, status: RECRUITING, city: Batumi, country: Georgia, geoPoint lat: 41.64228, lon: 41.63392, locations facility: SB Investigative Site, status: RECRUITING, city: Tbilisi, country: Georgia, geoPoint lat: 41.69411, lon: 44.83368, locations facility: SB Investigative Site, status: RECRUITING, city: Jaipur, country: India, geoPoint lat: 26.91962, lon: 75.78781, locations facility: SB Investigative Site, status: RECRUITING, city: Surat, country: India, geoPoint lat: 21.19594, lon: 72.83023, locations facility: SB Investigative Site, status: RECRUITING, city: Cluj-Napoca, country: Romania, geoPoint lat: 46.76667, lon: 23.6, locations facility: SB Investigative Site, status: RECRUITING, city: Craiova, country: Romania, geoPoint lat: 44.31667, lon: 23.8, locations facility: SB Investigative Site, status: RECRUITING, city: Sibiu, country: Romania, geoPoint lat: 45.8, lon: 24.15, locations facility: SB Investigative Site, status: RECRUITING, city: Madrid, country: Spain, geoPoint lat: 40.4165, lon: -3.70256, hasResults: False
protocolSection identificationModule nctId: NCT06348186, orgStudyIdInfo id: Fascial Tissue Response, briefTitle: Fascial Tissue Response To Manual Therapy: Implications In Long Covid Rehabilitation, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-01, primaryCompletionDateStruct date: 2024-04-01, completionDateStruct date: 2024-07-31, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: University of the State of Santa Catarina, class: OTHER, collaborators name: Larissa Sinhorim, descriptionModule briefSummary: According to the World Health Organization (WHO), as of mid-September 2022, more than 21 million Brazilians have recovered from COVID-19. However, post-infection symptoms continue to appear months after the end of the acute infection, a syndrome called long COVID. Therefore, the aim of this study is to investigate the responses of fascia-focused manual therapy in participants with long COVID., conditionsModule conditions: COVID-19, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Guidebook, interventions name: Guidebook and Myofascial Reorganization® (RMF)., outcomesModule primaryOutcomes measure: Functioning and disability, primaryOutcomes measure: Biomechanical and tissue viscoelastic properties, secondaryOutcomes measure: Work capacity, secondaryOutcomes measure: Quality of life, secondaryOutcomes measure: Upper limb dysfunctions, secondaryOutcomes measure: Balance, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Santa Catarina State University, status: RECRUITING, city: Florianópolis, state: Santa Catarina, zip: 88.035-001, country: Brazil, contacts name: Larissa Sinhorim, role: CONTACT, geoPoint lat: -27.59667, lon: -48.54917, hasResults: False
protocolSection identificationModule nctId: NCT06348173, orgStudyIdInfo id: 2021-2190, briefTitle: Response and Remission to Treatment With Anti-IL5/IL5R Antagonists, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-06-01, primaryCompletionDateStruct date: 2023-11-30, completionDateStruct date: 2023-11-30, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Université de Montréal, class: OTHER, collaborators name: GlaxoSmithKline, descriptionModule briefSummary: The aim of this retrospective observational study is to compare the response and remission rate after treatment with IL5/IL5-R antagonists in asthmatics who would and would have not met the inclusion criteria of the original randomized clinical trials.This study will be performed using the charts of the patients., conditionsModule conditions: Asthma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: RETROSPECTIVE, enrollmentInfo count: 109, type: ACTUAL, armsInterventionsModule interventions name: Mepolizumab, outcomesModule primaryOutcomes measure: Response to IL5/IL5R antagonists one year after cohort entry among subjects fulfilling and not fulfilling the original RCT inclusion criteria, primaryOutcomes measure: Remission rate with IL5/IL5R antagonists one year after cohort entry in subjects fulfilling and not fulfilling the original RCT inclusion criteria, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Hôpital du Sacré-Coeur de Montréal, city: Montréal, state: Quebec, zip: H4J 1C5, country: Canada, geoPoint lat: 45.50884, lon: -73.58781, hasResults: False
protocolSection identificationModule nctId: NCT06348147, orgStudyIdInfo id: LCCC2323, briefTitle: Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08, primaryCompletionDateStruct date: 2026-05, completionDateStruct date: 2028-08, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-10, sponsorCollaboratorsModule leadSponsor name: UNC Lineberger Comprehensive Cancer Center, class: OTHER, descriptionModule briefSummary: This Phase II hybrid decentralized trial will examine the effect of daratumumab-based quadruplet induction therapy administered at an attenuated schedule in subjects with newly diagnosed multiple myeloma (NDMM) who are eligible for standard-of-care autologous stem cell transplantation (ASCT). Daratumumab, lenalidomide, bortezomib, and dexamethasone (Dara-RVd) have recently become a standard induction regimen for patients with NDMM who are eligible for ASCT in the United States. As implemented in clinical trials, Dara-RVd involves twice weekly bortezomib administration, which is inconvenient for patients and may result in increased rates of limiting toxicity, such as peripheral neuropathy. Adoption of alternate schedules involving once-weekly bortezomib is common in real-world practice, however a paucity of prospective data supporting this practice exists.This study examines the efficacy of an attenuated Dara-RVd schedule involving once-weekly bortezomib dosing., conditionsModule conditions: Newly Diagnosed Multiple Myeloma, conditions: Multiple Myeloma, conditions: Autologous Stem Cell Transplantation, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 39, type: ESTIMATED, armsInterventionsModule interventions name: Daratumumab, interventions name: Lenalidomide, interventions name: Bortezomib, interventions name: Dexamethasone, outcomesModule primaryOutcomes measure: The rate of achievement of bone marrow minimal residual disease (MRD) negativity, secondaryOutcomes measure: Progression Free Survival (PFS ), secondaryOutcomes measure: Stringent complete response (sCR), secondaryOutcomes measure: Overall Survival (OS), secondaryOutcomes measure: Therapeutic discontinuation, secondaryOutcomes measure: Time to first response, secondaryOutcomes measure: Time to best response, secondaryOutcomes measure: Maximum depth of response (from PR to CR, including sCR), secondaryOutcomes measure: Overall response rate (ORR), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UNC Lineberger Comprehensive Cancer Center, city: Chapel Hill, state: North Carolina, zip: 27516, country: United States, contacts name: Ralph L Dessieu, role: CONTACT, email: ralph-lyne_dessieu@med.unc.edu, contacts name: Samuel M Rubinstein, MD, MSCI, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 35.9132, lon: -79.05584, hasResults: False
protocolSection identificationModule nctId: NCT06348134, orgStudyIdInfo id: IRB23-0502, briefTitle: Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2034-07-01, completionDateStruct date: 2036-07-01, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: University of Chicago, class: OTHER, descriptionModule briefSummary: Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery., conditionsModule conditions: Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, conditions: HER2-positive Breast Cancer, conditions: Breast Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 74, type: ESTIMATED, armsInterventionsModule interventions name: Trastuzumab emtansine, interventions name: Pertuzumab Injection, interventions name: Docetaxel, interventions name: Tamoxifen, interventions name: Letrozole, interventions name: Goserelin, outcomesModule primaryOutcomes measure: Pathological Complete Response, secondaryOutcomes measure: Reported Adverse Events and clinical/medical records of participants, secondaryOutcomes measure: Percentage of participants who are suitable for breast-conserving surgery, secondaryOutcomes measure: Event-free survival duration reported among participants, secondaryOutcomes measure: Quality of life reported among study participants, secondaryOutcomes measure: Genetic and epigenetic factors associated with breast cancer in Nigeria, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Chicago, city: Chicago, state: Illinois, zip: 60615, country: United States, contacts name: Olufunmilayo Olufunmilayo, role: CONTACT, phone: 773-702-1632, email: folopade@medicine.bsd.uchicago.edu, geoPoint lat: 41.85003, lon: -87.65005, hasResults: False
protocolSection identificationModule nctId: NCT06348121, orgStudyIdInfo id: WK2024003, briefTitle: Impact of Probiotics on Children With ADHD, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-07, primaryCompletionDateStruct date: 2024-08-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Wecare Probiotics Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: To evaluate the efficacy and safety of probiotic product WecProB as food supplements for the treatment of clinical symptoms in children with ADHD, in comparison with placebo., conditionsModule conditions: Attention Deficit Hyperactivity Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: Probiotic, outcomesModule primaryOutcomes measure: Clinical symptoms of ADHD, eligibilityModule sex: MALE, minimumAge: 6 Years, maximumAge: 14 Years, stdAges: CHILD, hasResults: False
protocolSection identificationModule nctId: NCT06348095, orgStudyIdInfo id: WK2024004, briefTitle: Effect of Probiotics on Viral Pneumonia, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-07, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Wecare Probiotics Co., Ltd., class: INDUSTRY, descriptionModule briefSummary: To evaluate the effectiveness and safety of compound probiotic in shortening the course of illness in children with viral pneumonia, in comparison with placebo., conditionsModule conditions: Viral Pneumonia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 72, type: ESTIMATED, armsInterventionsModule interventions name: Probiotic, interventions name: Placebo, outcomesModule primaryOutcomes measure: Respiratory syncytial virus (RSV) viral load, eligibilityModule sex: ALL, minimumAge: 6 Months, maximumAge: 3 Years, stdAges: CHILD, hasResults: False
protocolSection identificationModule nctId: NCT06348082, orgStudyIdInfo id: 2000036068, secondaryIdInfos id: 1R18HS029812-01, type: AHRQ, link: https://reporter.nih.gov/quickSearch/1R18HS029812-01, briefTitle: Project Women's Insomnia Sleep Health Equity Study (WISHES), acronym: Project WISHES, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2025-09, primaryCompletionDateStruct date: 2028-07, completionDateStruct date: 2028-07, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-05, sponsorCollaboratorsModule leadSponsor name: Yale University, class: OTHER, collaborators name: Department of Health and Human Services, descriptionModule briefSummary: The purpose of this study is to achieve health and healthcare equity by implementing an equity-focused, mindfulness-based sleep intervention to reduce stress and sleep deficiency-related cardiometabolic disease burden in Black women., conditionsModule conditions: Insomnia, conditions: Sleep Health, conditions: Cardiometabolic Health, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Hybrid Type 1 effectiveness/implementation study using a pragmatic randomized controlled trial (RCT) with MBTI and a waitlist control. Participants will be randomly assigned by a computer-generated sequence to either the MBTI or waitlist control in a 1:1 ratio using permuted blocks stratified by age (2 strata: ≤50 or postmenopausal age \>51) with random block sizes of 2 or 4 to reduce predictability., primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 340, type: ESTIMATED, armsInterventionsModule interventions name: Mindfulness-based therapy for insomnia (MBTI), outcomesModule primaryOutcomes measure: Change in Insomnia Severity, primaryOutcomes measure: Change in Perceived Stress, primaryOutcomes measure: Acceptability of Intervention (AIM), primaryOutcomes measure: Feasibility of Intervention (FIM), primaryOutcomes measure: Treatment Fidelity, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Yale School of Nursing Biobehavioral Lab, city: West Haven, state: Connecticut, zip: 06516, country: United States, geoPoint lat: 41.27065, lon: -72.94705, hasResults: False
protocolSection identificationModule nctId: NCT06348043, orgStudyIdInfo id: SU_PumpKIN, secondaryIdInfos id: 1UG3HL163311-01A1, type: NIH, link: https://reporter.nih.gov/quickSearch/1UG3HL163311-01A1, briefTitle: Pumps for Kids, Infants and Neonates (PumpKIN): The Jarvik 2015 Pivotal Trial, acronym: PumpKIN, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-08, primaryCompletionDateStruct date: 2028-12, completionDateStruct date: 2029-12, studyFirstPostDateStruct date: 2024-04-04, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, collaborators name: University of Texas, collaborators name: Carelon Research, collaborators name: National Heart, Lung, and Blood Institute (NHLBI), descriptionModule briefSummary: This is a 22-subject prospective, multicenter, single-arm clinical trial to evaluate the safety and effectiveness of the Jarvik 2015 left ventricular assist device (LVAD) as a bridge to heart transplant in children weighing 8 to 30 kilograms. Data generated from the study will be used to support FDA review and potential approval of the device under the Humanitarian Device Exemption (HDE) regulation, the FDA approval pathway for devices intended to treat rare and orphan diseases., conditionsModule conditions: Heart Failure With Reduced Ejection Fraction, conditions: Pediatric HD, Stage IV, conditions: LVAD, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 22, type: ESTIMATED, armsInterventionsModule interventions name: Jarvik 2015 LVAD, outcomesModule primaryOutcomes measure: Survival to heart transplant, recovery or 180 days of support in the absence of severe stroke., primaryOutcomes measure: Freedom from symptomatic stroke, secondaryOutcomes measure: Incidence rate of all protocol-defined SAE's through 180 days of support definitely or probably related to the device, secondaryOutcomes measure: Distribution of Pediatric Stroke Outcomes Measures, secondaryOutcomes measure: The KOSCHI score, secondaryOutcomes measure: Overall survival on Jarvik 2015 support to 180 days, eligibilityModule sex: ALL, minimumAge: 6 Months, maximumAge: 16 Years, stdAges: CHILD, contactsLocationsModule, hasResults: False